CM
OCUL icon

Castleark Management’s Ocular Therapeutix OCUL Stock Holding History

Castleark Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-485,837
Closed -$7.97M – 351
2021
Q1 		$7.97M Buy
485,837
+159,195
+49% +$3.07M 0.29% 102
2020
Q4 		$6.76M Buy
+326,642
New +$4.85M 0.25% 111

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Castleark Management's OCUL Position: Q2 2021 in Review

Castleark Management sold out of Ocular Therapeutix (OCUL) in Q2 2021, closing a stake of 485,837 shares — an estimated $7.97M sold.

Castleark Management first reported a position in OCUL in Q4 2020 and held it in 2 quarters. The position peaked at $7.97M in Q1 2021. 149 funds tracked by Wall St. Rank hold OCUL as of Q2 2021.

  • Castleark Management reported no remaining Ocular Therapeutix position as of Q2 2021 after selling out during the quarter.
  • Castleark Management sold 485,837 Ocular Therapeutix shares in Q2 2021, an estimated $7.97M.
  • Castleark Management first reported a position in Ocular Therapeutix in Q4 2020 and held it in 2 quarters.
  • Castleark Management's Ocular Therapeutix position peaked at $7.97M in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2021.

Based on Castleark Management's 13F filing for Q2 2021, filed 17 Aug 2021.